Dexcom Launches the First Generative AI Platform in Glucose Biosensing

Rhea-AI Summary

Dexcom (NASDAQ:DXCM) has launched the first-ever Generative AI platform in glucose biosensing technology. The platform, built on Google Cloud's Vertex AI and Gemini models, will analyze individual health data patterns to reveal connections between lifestyle choices and glucose levels. Stelo, Dexcom's FDA-cleared over-the-counter glucose biosensor, is the first product to implement this GenAI technology through enhanced Weekly Insights, providing users with personalized recommendations on diet, exercise, and sleep.

The company plans to introduce additional GenAI-powered features throughout the next year to help users better understand their health information and make informed lifestyle decisions. This innovation reinforces Dexcom's position as a leader in glucose biosensing technology.

Positive

• First-to-market advantage with proprietary GenAI platform integration in glucose biosensing
• Strategic partnership with Google Cloud leveraging advanced AI technology
• Expansion of product capabilities through AI-enhanced personalized insights
• Potential for future revenue growth through planned GenAI features across product portfolio

Negative

• None.

Insights

Tech Expert

The integration of Google Cloud's Vertex AI and Gemini models into Dexcom's glucose biosensing technology marks a significant advancement in personalized healthcare. This proprietary GenAI platform will analyze health data patterns to provide actionable insights, starting with the Stelo product line. The platform's ability to contextualize multiple health metrics (glucose, activity, sleep) and deliver personalized recommendations represents a competitive advantage in the CGM market. This technology infrastructure positions Dexcom for future AI-driven innovations across their product portfolio, potentially increasing user engagement and product stickiness. The partnership with Google Cloud also provides scalability and robust AI capabilities, essential for handling sensitive healthcare data.

Medical Research Analyst

The launch of GenAI in glucose biosensing could significantly improve patient outcomes by providing more personalized and contextual health insights. The system's ability to correlate lifestyle choices with glucose patterns enables better-informed decision-making for metabolic health management. Particularly notable is the implementation in Stelo, their OTC glucose biosensor, which expands access to sophisticated glucose monitoring beyond traditional diabetic patients. This positions Dexcom to capture a broader market segment interested in metabolic health optimization. The technology's ability to deliver weekly personalized insights based on multiple health parameters represents a shift toward more comprehensive and preventative healthcare monitoring.

• Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform
• Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and Gemini models and will initially enhance Stelo’s Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep
• Proprietary platform lays foundation for future GenAI advancements across the Dexcom product portfolio that will further empower its millions of users to help take control of their health
• Dexcom to speak on the future of health AI at CES 2025

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.¹ The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health.

Stelo, the first over-the-counter glucose biosensor cleared² by the FDA in the United States, is the first Dexcom product to use GenAI-enabled technology to produce weekly insights. The enhancement of Stelo’s Weekly Insights feature started rolling out to users this week. GenAI-powered messaging enhances Stelo’s existing Weekly Insights by offering users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app.

“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualize their health information and make proactive, informed lifestyle decisions.”

Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform.

“By bringing the power of Google Cloud’s Vertex AI and Gemini to Dexcom’s innovative glucose biosensing technology, users will have more personalized insights to help them make the best decisions for their health,” said Chris Sakalosky, vice president of Strategic Industries for Google Cloud. “Dexcom is empowering people to take control of their metabolic health like never before, and it’s just the beginning of what’s possible as leading organizations bring GenAI to healthcare.”

Leach will join other industry leaders on a panel at CES 2025 to speak to Health AI in 2030. The panel of experts will discuss how AI will revolutionize health care over the next five years and will be held on Jan. 8, 2025, at 2 p.m. PT at the Venetian on level 4 in Marcello 4404. Learn more about the panel here.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

¹ Dexcom, Data on file, 2024. ² Dexcom, Stelo User Guide, 2024.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.

INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2024 Dexcom, Inc. All rights reserved.

Category: IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20241217011997/en/

Media Contact

Janika Kelly

mediarelations@dexcom.com



Investor Contact

Sean Christensen

investor-relations@dexcom.com

Source: DexCom, Inc.

FAQ

What is Dexcom's new GenAI platform and how does it work with Stelo?

Dexcom's GenAI platform analyzes health data patterns to connect lifestyle choices with glucose levels, initially enhancing Stelo's Weekly Insights feature by providing personalized recommendations on diet, exercise, and sleep.

How is Google Cloud involved in Dexcom's (DXCM) new AI initiative?

Dexcom is using Google Cloud's Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform for glucose biosensing technology.

When will DXCM implement additional GenAI features across its product portfolio?

Dexcom plans to introduce additional GenAI-powered features throughout the next year across its product portfolio.

What makes Stelo different from other Dexcom products?

Stelo is Dexcom's first over-the-counter glucose biosensor cleared by the FDA and the first product to implement their new GenAI technology for personalized insights.

How will the new GenAI platform benefit DXCM users?

The platform will provide users with more personalized tips, recommendations, and education related to diet, exercise, and sleep, helping them make more informed lifestyle decisions based on their glucose data.